enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Novartis - Wikipedia

    en.wikipedia.org/wiki/Novartis

    Novartis fought a seven-year, controversial battle to patent Gleevec in India, and took the case all the way to the Indian Supreme Court, where the patent application was finally rejected. The patent application at the center of the case was filed by Novartis in India in 1998, after India had agreed to enter the World Trade Organization and to ...

  3. Novartis v. Union of India & Others - Wikipedia

    en.wikipedia.org/wiki/Novartis_v._Union_of_India...

    Novartis v. Union of India & Others is a landmark decision by a two-judge bench of the Indian Supreme Court on the issue of whether Novartis could patent Gleevec in India, and was the culmination of a seven-year-long litigation fought by Novartis. The Supreme Court upheld the Indian patent office's rejection of the patent application.

  4. Zhou Yiqing - Wikipedia

    en.wikipedia.org/wiki/Zhou_Yiqing

    They applied for patent in 1991, but granted only in 2002. In 1992 they got it registered as a new drug. Novartis then noticed the new drug and made a deal for mass production. [1] In 1999 Novartis obtained the international licensing rights and gave the brand name Coartem. It was approved by the US Food and Drug Administration in 2009. [4]

  5. Lutetium (177Lu) vipivotide tetraxetan - Wikipedia

    en.wikipedia.org/wiki/Lutetium_(177Lu)_vipivot...

    In 2017, the ABX patent was also acquired by Endocyte [16] and Endocyte together with the above two sets of patents was acquired by Novartis in 2018. [17] Efficacy and safety was initially investigated as a compassionate access treatment in Germany with high tumor targeting and low doses to normal organs. [18]

  6. Bimagrumab - Wikipedia

    en.wikipedia.org/wiki/Bimagrumab

    In April 2016, Novartis announced that bimagrumab had failed a Phase IIb/III study for sporadic inclusion body myositis. [6] In January 2021, a new study confirmed that treatment with Bimagrumab is safe and effective for treating excess adiposity and metabolic disturbances of adult patients with obesity and type 2 diabetes. [ 7 ]

  7. Proprietary drug - Wikipedia

    en.wikipedia.org/wiki/Proprietary_drug

    Novartis had filed a patent for Glivec in 1997. [30] An exclusive marketing right was also granted for Novartis in 2003 and the application were approved in 2005 . [ 30 ] In 2013, the Supreme Court of India upheld the rejection of the patent application of Glivec by Novartis , [ 31 ] ending the 10-years battle between the proprietary drug ...

  8. Advanced Accelerator Applications - Wikipedia

    en.wikipedia.org/wiki/Advanced_Accelerator...

    Advanced Accelerator Applications (AAA or Adacap) is a France-based pharmaceutical group, specialized in the field of nuclear medicine. [1] The group operates in all three segments of nuclear medicine (PET, SPECT and therapy) to diagnose and treat serious conditions in the fields of oncology, neurology, cardiology, infectious and inflammatory diseases.

  9. Cetus Corporation - Wikipedia

    en.wikipedia.org/wiki/Cetus_Corporation

    Cetus was founded in 1971 by Ronald E. Cape, Peter Farley, and Nobelist Donald A. Glaser.Its early efforts involved automated methods to select for industrial microorganisms that could produce greater amounts of chemical feedstocks, antibiotics, or vaccine components.